Robeauté

Robeauté, founded in 2017 and headquartered in France, is at the forefront of revolutionizing brain healthcare through its pioneering work with therapeutic microrobots. These robots are described by the company as being smaller than a grain of rice and are designed to diagnose, treat, and monitor brain activity with unmatched precision and adaptability.

Positioned at the intersection of microrobotics, engineering, and medicine, Robeauté thrives on a culture that welcomes both conventional and unconventional thinkers, fostering a multidisciplinary and multicultural team. This approach underlines their commitment to innovation and collaboration in a rapidly evolving technological landscape.

The company recently secured a €2.50M Series A investment on 01 February 2025, with funding led by the European Innovation Council. This injection of capital positions Robeauté to further expand its capabilities and attract top-tier talent, ensuring sustained momentum in its mission to reshape brain healthcare.